Levetiracetam Tablet, Film Coated
Product Images NDC 43063-617

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43063-617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063617 Label (43063617)

This is a description of a package of Levitiracetam USP tablets containing 60 tablets, each containing 500mg of Levitiracetam. The package has details of the reorder number, lot number, and expiry date. The tablets are oblong and scored and are yellow in color. Patients are advised to take the tablets as per their doctor's advice and consult their doctor about any side effects. The rest of the text appears to be errors and not useful information.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01

This text appears to be a formula for calculating the total daily dose of a medication based on the patient's weight and the daily dose per kilogram of body weight, given that the medication concentration is 100 mg/mL.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02

This appears to be a formula for calculating creatinine clearance (CLer), which is an important measure of kidney function. The formula accounts for the patient's age, weight, and serum creatinine levels, and can be adjusted for body surface area. The exact purpose and context of this formula is not clear without further information.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05

This is a table showing the percentages of patients in different groups taking different dosages of Levetiracetam and Placebo. The dosages of Levetiracetam mentioned in the table are 1000 mg/day and 2000 mg/day, and the total number of patients in each group is also mentioned.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07

This is a table showing the percentage of patients who fall under certain categories in two groups, one treated with placebo and another treated with levetiracetam. However, it is difficult to interpret the table without the appropriate headings for the categories mentioned above.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08

This text appears to represent data on the responses of patients to placebo and levetiracetam. It indicates that of the 51 patients who received placebo, 19.6% exhibited the response being measured. In contrast, of the 58 patients who received levetiracetam, 43.1% exhibited the response being measured.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09

The given text shows the percentage of patients and their corresponding values of improvement in a study with Placebo and Levetiracetam drugs. The drugs were tested on a total of 163 patients, 84 of which received Placebo while 79 received Levetiracetam. The study does not provide any additional information or context.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.